Patents by Inventor Norman M. Kneteman

Norman M. Kneteman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8445745
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: May 21, 2013
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Publication number: 20120309032
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Application
    Filed: May 30, 2012
    Publication date: December 6, 2012
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Patent number: 8212106
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: July 3, 2012
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Publication number: 20110167507
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Application
    Filed: July 20, 2010
    Publication date: July 7, 2011
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Patent number: 7781642
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: August 24, 2010
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Publication number: 20100104555
    Abstract: The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus. The invention provides modified hepatitis C virus E2 polypeptides, preparations and pharmaceutical compositions containing them, as well as methods for using these modified E2 polypeptides.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 29, 2010
    Applicant: The Scripps Research Institute
    Inventors: Mansun Law, Toshiaki Maruyama, Dennis R. Burton, Jonathan K. Ball, Norman M. Kneteman
  • Publication number: 20090151012
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Application
    Filed: December 11, 2008
    Publication date: June 11, 2009
    Inventors: NORMAN M. KNETEMAN, D. Lorne Tyrrell, David Frederick Mercer
  • Patent number: 7498479
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 3, 2009
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Patent number: 7273963
    Abstract: The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: September 25, 2007
    Assignees: KMT Hepatech, Inc., University of Maryland, Baltimore
    Inventors: Norman M. Kneteman, John B. Sacci, Jr., D. Lorne Tyrrell, John F. Elliott, Abdu F. Azad
  • Patent number: 7161057
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: January 9, 2007
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Publication number: 20040043949
    Abstract: The invention provides anti-pathogen polypeptide and polynucleotide compositions, and methods of use. In general, the composition of the invention provide a modified pro-polypeptide comprising a pro-domain, a pathogen protease cleavage site, and a cytotoxic domain which can be activated by cleavage of the pro-polypeptide by a protease of an intracellular pathogen. The invention further provides nucleic acids encoding the subject polypeptides, and vectors and host cells comprising the subject nucleic acids. Cleavage of the pro-polypeptide by the pathogen protease results in activation of the cytotoxic domain, and decreases the viability of the pathogen-infected host cell. Methods for using the subject nucleic acids and polypeptides to reduce the viability of a pathogen-infected cell, and for reducing the pathogen load of a subject infected with a pathogen are provided. The invention further provides kits for carrying out the subject methods.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 4, 2004
    Inventors: Christopher Richardson, Eric C. Hsu, David Lorne Tyrrell, Norman M. Kneteman
  • Publication number: 20030115616
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Application
    Filed: September 12, 2002
    Publication date: June 19, 2003
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Patent number: 6509514
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: January 21, 2003
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer